| Identification | Back Directory | [Name]
BIBF 1202 | [CAS]
894783-71-2 | [Synonyms]
CS-1313
BIBF 1202
Nintedanib-1
Nintedanib-010
Intedanib Impurity A
Nintedanib impurity A
Nintedanib impuritiesA
Nintedanib impurities26
NintedanibImpurity6-13C-d3
Nintedanib Carboxylic Acid
(Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1
-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylic acid
(3Z)-2,3-Dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid
1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, (3Z)-
Nintedanib impurity 9/Nintedanib Carboxylic Acid/(Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1 -yl)acetamido)phenyl)amino)(phenyl) methylene)-2-oxoindoline-6-carboxylic acid
Nintedanib Impurity 6Q: What is
Nintedanib Impurity 6 Q: What is the CAS Number of
Nintedanib Impurity 6 Q: What is the storage condition of
Nintedanib Impurity 6 Q: What are the applications of
Nintedanib Impurity 6 | [Molecular Formula]
C30H31N5O4 | [MDL Number]
MFCD28167767 | [MOL File]
894783-71-2.mol | [Molecular Weight]
525.6 |
| Chemical Properties | Back Directory | [Melting point ]
>216°C (dec.) | [Boiling point ]
759.5±60.0 °C(Predicted) | [density ]
1.331±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Aqueous Base (Slightly, Heated) | [form ]
Solid | [pka]
3.94±0.20(Predicted) | [color ]
Light Yellow to Yellow |
| Hazard Information | Back Directory | [Description]
BIBF 1202 is an active metabolite of the VEGFR, FGFR, and PDGFR inhibitor BIBF 1120 (nintedanib; ). It is formed from BIBF 1120 by intracellular esterases. BIBF 1202 inhibits VEGFR2 with an IC50 value of 62 nM. | [Uses]
Nintedanib Carboxylic Acid is a related compound of Intedanib (I666650), an indolinone derivative that inhibits angiokinase and an antitumor agent. | [storage]
Store at -20°C | [References]
[1] FRANK HILBERG. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.[J]. Cancer research, 2008, 68 12: 4774-4782. DOI: 10.1158/0008-5472.can-07-6307
[2] DAN LIN . Simultaneous determination of nintedanib and its metabolite by UPLC–MS/MS in rat plasma and its application to a pharmacokinetic study[J]. Journal of pharmaceutical and biomedical analysis, 2016, 117: Pages 173-177. DOI: 10.1016/j.jpba.2015.08.024 |
|
|